SGLT2i and postglomerular vasodilation
- PMID: 32200864
- DOI: 10.1016/j.kint.2020.01.007
SGLT2i and postglomerular vasodilation
Comment in
-
The authors reply.Kidney Int. 2020 Apr;97(4):806. doi: 10.1016/j.kint.2020.01.008. Kidney Int. 2020. PMID: 32200865 No abstract available.
Comment on
-
The renal hemodynamic effects of the SGLT2 inhibitor dapagliflozin are caused by post-glomerular vasodilatation rather than pre-glomerular vasoconstriction in metformin-treated patients with type 2 diabetes in the randomized, double-blind RED trial.Kidney Int. 2020 Jan;97(1):202-212. doi: 10.1016/j.kint.2019.09.013. Epub 2019 Oct 10. Kidney Int. 2020. PMID: 31791665 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical